Bank of Montreal vs Zoetis Inc — how do they compare? Bank of Montreal trades at $182.04 (market cap $127.25B), while Zoetis Inc trades at $75.11 (market cap $30.92B). The key difference: Bank of Montreal is far larger — about 4.1× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.83%). Which is the better fit depends on your goals.
| BMO | ZTS | |
|---|---|---|
Market Cap | $127.25B | $30.92B |
Sector | Financials | Health |
52-Week High | $183.65 | $156.76 |
52-Week Low | $112.54 | $71.91 |
Dividend Yield | 2.68% | 2.83% |
Enterprise Value | — | $38.49B |
Signals from Pluang's Aura AI — not financial advice
BMO trades at $181.55, up 0.4% with a bullish technical signal. The company has consistently beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS expected at $2.66. Recent strategic moves include the $1.44 billion sale of Moneris and the acquisition of Euroz Hartleys' Australian capital markets business, strengthening its global metals and mining franchise. The stock shows strong fundamental performance with 25.92% net income margin and 11.05% ROE.
BMO presents a balanced investment case with solid earnings momentum and strategic expansion, though trading near resistance at $182. Key opportunities include consistent dividend payments and global banking recognition, while risks involve interest rate sensitivity and competitive pressures in the North American banking sector.
No Aura AI signal available yet.
Trailing returns across standard periods
Bank of Montreal is a diversified financial-services provider based in North America, operating four business segments: Canadian personal and commercial banking, U.S. P&C banking, wealth management, and capital markets. The bank's operations are primarily in Canada, with a material portion also in the U.S.
Read more on BMO →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →